Cargando…
Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment
Application of tumor genome sequencing has identified numerous loss-of-function alterations in cancer cells. While these alterations are difficult to target using direct interventions, they may be attacked with the help of the synthetic lethality (SL) approach. In this approach, inhibition of one ge...
Autores principales: | Paul, James M., Toosi, Behzad, Vizeacoumar, Frederick S., Bhanumathy, Kalpana Kalyanasundaram, Li, Yue, Gerger, Courtney, Zawily, Amr El, Freywald, Tanya, Anderson, Deborah H., Mousseau, Darrell, Kanthan, Rani, Zhang, Zhaolei, Vizeacoumar, Franco J., Freywald, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226566/ https://www.ncbi.nlm.nih.gov/pubmed/27418135 http://dx.doi.org/10.18632/oncotarget.10569 |
Ejemplares similares
-
The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment
por: El Zawily, Amr, et al.
Publicado: (2017) -
The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation
por: El Zawily, Amr M., et al.
Publicado: (2016) -
EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours
por: Toosi, Behzad M., et al.
Publicado: (2018) -
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
por: K. Bhanumathy, Kalpana, et al.
Publicado: (2021) -
An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer
por: Auslander, Noam, et al.
Publicado: (2017)